We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems

By LabMedica International staff writers
Posted on 09 Feb 2024

Sysmex Corporation (Kobe, Japan) and Hitachi High-Tech Corporation (Tokyo, Japan) have entered into a collaboration for the development of genetic testing systems using capillary electrophoresis sequencers (CE sequencers). More...

This collaboration stems from the outcomes of joint research conducted since the signing of a feasibility study (FS) agreement in August 2023, which focused on creating new genetic testing systems. The goal of Sysmex and Hitachi High-Tech is to produce genetic testing systems that are more efficient and cost-effective, thereby facilitating the widespread clinical application of personalized genetic testing for various diseases.

The field of genetic testing has seen significant advancements in assay reagent development using next-generation sequencing (NGS). However, there are challenges such as reducing measurement times and operational costs, underscoring the need for novel genetic testing systems suitable for widespread clinical use. To address these challenges, the companies signed the FS agreement in August 2023. The agreement aimed at exploring the development of new genetic testing systems that could offer optimal genetic analysis for individual diseases. This would be achieved by combining Hitachi High-Tech’s CE sequencer technology with Sysmex’s expertise in NGS reagent development and analysis technology, both honed through the advancement of genomic medicine in clinical settings.

Having met the objectives outlined in the FS agreement, Sysmex and Hitachi High-Tech have now agreed to proceed with the development of genetic testing systems intended for broad clinical use. Hitachi High-Tech will focus on obtaining medical device approvals for their CE sequencers, while Sysmex will develop and seek regulatory approvals for testing reagents compatible with these devices, as well as developing analysis software. Initially, the collaboration will concentrate on applications in oncology before gradually extending to other disease areas. By leveraging each company’s unique technologies and expertise, Sysmex and Hitachi High-Tech aim to promote the adoption of new genetic testing systems that offer shorter measurement durations and reduced operational costs.

Related Links:
Sysmex Corporation
Hitachi High-Tech Corporation


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Manual Pipetting Aid
Pipette Controllers macro
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.